507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819095350049243136 |
|---|---|
| author | Anna Olsson-Brown Joseph Sacco Mark Middleton Kevin Harrington Robert Coffin Andrea Pirzkall Praveen Bommareddy Isla Leslie Francesca Aroldi Pablo Nenclares Tze Chan Imran Saleem Henry Castro |
| author_facet | Anna Olsson-Brown Joseph Sacco Mark Middleton Kevin Harrington Robert Coffin Andrea Pirzkall Praveen Bommareddy Isla Leslie Francesca Aroldi Pablo Nenclares Tze Chan Imran Saleem Henry Castro |
| author_sort | Anna Olsson-Brown |
| collection | DOAJ |
| first_indexed | 2024-12-21T23:41:54Z |
| format | Article |
| id | doaj.art-d1aa5ab6afc849d2b95d01f6b52502df |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-21T23:41:54Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-d1aa5ab6afc849d2b95d01f6b52502df2022-12-21T18:46:13ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.507507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumorsAnna Olsson-Brown0Joseph Sacco1Mark Middleton2Kevin Harrington3Robert Coffin4Andrea Pirzkall5Praveen Bommareddy6Isla Leslie7Francesca Aroldi8Pablo Nenclares9Tze Chan10Imran Saleem11Henry Castro121 Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK8 Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, UKAff12 grid.451056.30000000121163923National Institute for Health Research Biomedical Research Centre London UKRadiotherapy and Imaging, The Institute of Cancer Research, London, UKAff14 grid.417886.40000 0001 0657 5612Amgen Woburn MA USAAff3 0000 0004 0534 4718grid.418158.1Genentech, Inc. South San Francisco CA USA10Replimune, Woburn, MA, USAHead and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK1University of Oxford, Oxford, UKHead and Neck Unit, Royal Marsden Hospital NHS Trust, London, UK4Royal Liverpool University Hospital, Liverpool, UK5Replimune, Woburn, MA, USA5Replimune, Woburn, MA, USA |
| spellingShingle | Anna Olsson-Brown Joseph Sacco Mark Middleton Kevin Harrington Robert Coffin Andrea Pirzkall Praveen Bommareddy Isla Leslie Francesca Aroldi Pablo Nenclares Tze Chan Imran Saleem Henry Castro 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors Journal for ImmunoTherapy of Cancer |
| title | 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors |
| title_full | 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors |
| title_fullStr | 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors |
| title_full_unstemmed | 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors |
| title_short | 507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors |
| title_sort | 507 a phase 1 clinical trial of rp2 an enhanced potency oncolytic hsv expressing an anti ctla 4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors |
| work_keys_str_mv | AT annaolssonbrown 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT josephsacco 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT markmiddleton 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT kevinharrington 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT robertcoffin 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT andreapirzkall 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT praveenbommareddy 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT islaleslie 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT francescaaroldi 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT pablonenclares 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT tzechan 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT imransaleem 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors AT henrycastro 507aphase1clinicaltrialofrp2anenhancedpotencyoncolytichsvexpressinganantictla4antibodyasasingleagentandcombinedwithnivolumabinpatientswithadvancedsolidtumors |